Global pharma majors expand advanced therapies in India
India’s pharmaceutical sector is witnessing global majors deepening their footprint in advanced therapies.
The Central Drugs Standard Control Organization (CDSCO) has granted US drug major Eli Lilly (NYSE: LLY) India subsidiary approval for Kisunla (donanemab), a breakthrough treatment for patients in the early stages of Alzheimer’s disease, marking a milestone in neurological care.
On the same day, UK-based AstraZeneca (LSE: AZN) Pharma India unit and Sun Pharmaceutical (BOM: 524715) announced an exclusive brand partnership to expand access to sodium zirconium cyclosilicate (SZC) for hyperkalaemia, underscoring the growing push to bring cutting-edge medicines to Indian patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze